B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 11.68 HKD 2.46% Market Closed
Market Cap: 4.7B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+111%
Revenue
Forecast
+13%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Biocytogen Pharmaceuticals Beijing Co Ltd

Wall Street analysts forecast Biocytogen Pharmaceuticals Beijing Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Biocytogen Pharmaceuticals Beijing Co Ltd is 15.17 HKD with a low forecast of 13.62 HKD and a high forecast of 17.06 HKD.

Lowest Forecast
Wall Street Target
13.62 HKD
17% Upside
Average Forecast
Wall Street Target
15.17 HKD
30% Upside
Highest Forecast
Wall Street Target
17.06 HKD
46% Upside
Lowest
Price Target
13.62 HKD
17% Upside
Average
Price Target
15.17 HKD
30% Upside
Highest
Price Target
17.06 HKD
46% Upside
Biocytogen Pharmaceuticals Beijing Co Ltd Competitors:
Price Targets
GLPG
Galapagos NV
32% Upside
N
4893
Noile-Immune Biotech Inc
210% Upside
BBIO
BridgeBio Pharma Inc
56% Upside
H
301207
Hualan Biological Bacterin Inc
25% Upside
GLPG
Galapagos NV
32% Upside
N
4893
Noile-Immune Biotech Inc
210% Upside
BBIO
BridgeBio Pharma Inc
56% Upside
H
301207
Hualan Biological Bacterin Inc
25% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
62% Upside
E
206650
EuBiologics Co Ltd
33% Upside
TWST
Twist Bioscience Corp
37% Upside
RAPT
Rapt Therapeutics Inc
480% Upside

Revenue
Forecast

Revenue Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

For the last 3 years the compound annual growth rate for Biocytogen Pharmaceuticals Beijing Co Ltd's revenue is 40%. The projected CAGR for the next 3 years is 24%.

40%
Past Growth
24%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

The compound annual growth rate of Biocytogen Pharmaceuticals Beijing Co Ltd's operating income for the next 2 years is 40%.

N/A
Past Growth
40%
Estimated Growth
Estimates Accuracy
24%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

The compound annual growth rate of Biocytogen Pharmaceuticals Beijing Co Ltd's net income for the next 3 years is 112%.

N/A
Past Growth
112%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's stock price target?
Price Target
15.17 HKD

According to Wall Street analysts, the average 1-year price target for Biocytogen Pharmaceuticals Beijing Co Ltd is 15.17 HKD with a low forecast of 13.62 HKD and a high forecast of 17.06 HKD.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Revenue forecast?
Projected CAGR
24%

For the last 3 years the compound annual growth rate for Biocytogen Pharmaceuticals Beijing Co Ltd's revenue is 40%. The projected CAGR for the next 3 years is 24%.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Operating Income forecast?
Projected CAGR
40%

The compound annual growth rate of Biocytogen Pharmaceuticals Beijing Co Ltd's operating income for the next 2 years is 40%.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Net Income forecast?
Projected CAGR
112%

The compound annual growth rate of Biocytogen Pharmaceuticals Beijing Co Ltd's net income for the next 3 years is 112%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.